(Q34139151)

31 July 2017

1 reference

title

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug (English)

1 reference

31 July 2017

1 reference

Renaud Capdeville

1

1 reference

31 July 2017

Elisabeth Buchdunger

series ordinal

2

1 reference

31 July 2017

Juerg Zimmermann

series ordinal

3

1 reference

31 July 2017

Alex Matter

series ordinal

4

1 reference

31 July 2017

1 July 2002

1 reference

Nature Reviews Drug Discovery

31 July 2017

1 reference

31 July 2017

1

1 reference

31 July 2017

493-502

1 reference

31 July 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd839

31 July 2017

0 references

cites work

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

31 March 2020

1 reference

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

31 March 2020

1 reference

Acute leukaemia in bcr/abl transgenic mice

31 March 2020

1 reference

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

31 March 2020

1 reference

Drug-like properties and the causes of poor solubility and poor permeability

31 March 2020

1 reference

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

31 March 2020

1 reference

ARG tyrosine kinase activity is inhibited by STI571.

31 March 2020

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

31 March 2020

1 reference

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

31 March 2020

1 reference

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148

31 March 2020

1 reference

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

31 March 2020

1 reference

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.

31 March 2020

1 reference

Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL

31 March 2020

1 reference

BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway

31 March 2020

1 reference

Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells

31 March 2020

1 reference

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

31 March 2020

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

31 March 2020

1 reference

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

31 March 2020

1 reference

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

31 March 2020

1 reference

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

31 March 2020

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

Roots of clinical resistance to STI-571 cancer therapy

31 March 2020

1 reference

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

31 March 2020

1 reference

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

31 March 2020

1 reference

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

31 March 2020

1 reference

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

31 March 2020

1 reference

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

31 March 2020

1 reference

Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases

31 March 2020

1 reference

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

31 March 2020

1 reference

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

31 March 2020

1 reference

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

31 March 2020

1 reference

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

31 March 2020

1 reference

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

31 March 2020

1 reference

Involvement of platelet-derived growth factor in disease: development of specific antagonists

31 March 2020

1 reference

Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.

31 March 2020

1 reference

A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein

31 March 2020

1 reference

Beta 1 integrin-mediated collagen gel contraction is stimulated by PDGF.

31 March 2020

1 reference

A novel physiological function for platelet-derived growth factor-BB in rat dermis

31 March 2020

1 reference

Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling

31 March 2020

1 reference

Delivery of molecular medicine to solid tumors

31 March 2020

1 reference

Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD839

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference